Skip to main content
INDOCO · Health Care · 2026-08-07

Indoco Remedies Ltd

3.2WatchWeak -0.2Stage 2 · wk 2In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹221.7
-0.05% today
₹2,044 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Visit company website →
ROE
-10.1%
Profit margin -5.2%
Dividend Yield
0.10%
P/B 1.8
vs 52W High
-30.2%
₹164 lo₹317.6 hi
30.2% below 52W high — far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
-2.3%
200 DMA: ₹226.9 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.06x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -3.9% vs MA50 +3.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #79 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #53 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 14w
S4 14w
S4 16w
S4 21w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 3w → S1 7w → S4 7w → S1 9w → S4 1w → S3 1w → S2 14w → S3 8w → S4 14w → S1 8w → S2 5w → S3 2w → S4 7w → S1 3w → S4 16w → S1 8w → S2 8w → S3 13w → S4 21w → S1 12w → S2 1w current
Total tracked: 167 weeks across 21 stage runs.
1M
-13.1%
3M
-2.7%
6M
+4.6%
YTD
-1.8%
1Y
-31.6%
Scan Membership
Breakout Watch
Latest: 2026-07-29
3 appearances in last 60 days. First seen: 2024-09-26.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 2 · Vol x
2026-08-06S2
Wk 2 · Vol x
2026-08-05S2
Wk 2 · Vol x
2026-08-04S2
Wk 1 · Vol x
2026-08-03S2
Wk 1 · Vol x
2026-07-31S2
Wk 1 · Vol x
2026-07-30S2
Wk 1 · Vol x
2026-07-29S21→2
Wk 1 · Vol x
2026-07-28S1
Wk 12 · Vol x
2026-07-27S1
Wk 11 · Vol x
2026-07-24S1
Wk 11 · Vol x
2026-07-23S1
Wk 11 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹232.4
200 DMA
₹226.9
52W High
₹317.6
52W Low
₹164
5D Low
₹221.7
Resistance levels (recent highs)
20d High
₹259
60d High
₹260.2
120d High
₹260.2
250d High
₹308.6
Next resistance
+16.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.